Logo image of INBX

INHIBRX BIOSCIENCES INC (INBX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INBX - US45720N1037 - Common Stock

79.27 USD
-0.94 (-1.17%)
Last: 12/29/2025, 8:00:02 PM
79.1 USD
-0.17 (-0.21%)
Pre-Market: 12/30/2025, 7:31:33 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INBX. INBX was compared to 530 industry peers in the Biotechnology industry. While INBX seems to be doing ok healthwise, there are quite some concerns on its profitability. INBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year INBX has reported negative net income.
INBX had a negative operating cash flow in the past year.
In the past 5 years INBX reported 4 times negative net income.
In the past 5 years INBX always reported negative operating cash flow.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

INBX has a Return On Assets of 950.90%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
With an excellent Return On Equity value of 4582.06%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROIC N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

With an excellent Profit Margin value of 843786.00%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
INBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 843786%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 200K 400K 600K 800K

More info and screens

4

2. Health

2.1 Basic Checks

INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
INBX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for INBX has been reduced compared to 5 years ago.
There is no outstanding debt for INBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

INBX has an Altman-Z score of -2.08. This is a bad value and indicates that INBX is not financially healthy and even has some risk of bankruptcy.
INBX has a Altman-Z score of -2.08. This is comparable to the rest of the industry: INBX outperforms 50.00% of its industry peers.
A Debt/Equity ratio of 2.71 is on the high side and indicates that INBX has dependencies on debt financing.
INBX has a Debt to Equity ratio of 2.71. This is amonst the worse of the industry: INBX underperforms 80.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Altman-Z -2.08
ROIC/WACCN/A
WACC8.88%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.49 indicates that INBX has no problem at all paying its short term obligations.
INBX has a Current ratio of 4.49. This is comparable to the rest of the industry: INBX outperforms 51.89% of its industry peers.
INBX has a Quick Ratio of 4.49. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
INBX has a Quick ratio (4.49) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for INBX have decreased strongly by -108.39% in the last year.
INBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -88.89%.
INBX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.75% yearly.
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A

3.2 Future

INBX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.88% yearly.
INBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 319.07% yearly.
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INBX. In the last year negative earnings were reported.
Also next year INBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A cheap valuation may be justified as INBX's earnings are expected to decrease with -26.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INBX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (12/29/2025, 8:00:02 PM)

Premarket: 79.1 -0.17 (-0.21%)

79.27

-0.94 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-16 2026-03-16
Inst Owners54.24%
Inst Owner Change1.03%
Ins Owners15.57%
Ins Owner Change0%
Market Cap1.15B
Revenue(TTM)200.00K
Net Income(TTM)1.69B
Analysts43.33
Price Target12.24 (-84.56%)
Short Float %11.31%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.1%
Min EPS beat(2)-30.11%
Max EPS beat(2)34.31%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-30.11%
Max EPS beat(4)34.31%
EPS beat(8)4
Avg EPS beat(8)429.75%
EPS beat(12)4
Avg EPS beat(12)281.7%
EPS beat(16)6
Avg EPS beat(16)208.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.62%
EPS NY rev (1m)-10.91%
EPS NY rev (3m)-10.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5762.93
P/FCF N/A
P/OCF N/A
P/B 31.29
P/tB 31.29
EV/EBITDA N/A
EPS(TTM)-10.02
EYN/A
EPS(NY)-4.85
Fwd EYN/A
FCF(TTM)-9.87
FCFYN/A
OCF(TTM)-9.86
OCFYN/A
SpS0.01
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 843786%
GM N/A
FCFM N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.8%
Cap/Sales 23.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -2.08
F-Score3
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)185.13%
Cap/Depr(5y)152.08%
Cap/Sales(3y)528.39%
Cap/Sales(5y)321.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%
EBIT growth 1Y-51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.18%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBRX BIOSCIENCES INC / INBX FAQ

What is the fundamental rating for INBX stock?

ChartMill assigns a fundamental rating of 2 / 10 to INBX.


What is the valuation status of INHIBRX BIOSCIENCES INC (INBX) stock?

ChartMill assigns a valuation rating of 0 / 10 to INHIBRX BIOSCIENCES INC (INBX). This can be considered as Overvalued.


How profitable is INHIBRX BIOSCIENCES INC (INBX) stock?

INHIBRX BIOSCIENCES INC (INBX) has a profitability rating of 2 / 10.


What is the financial health of INHIBRX BIOSCIENCES INC (INBX) stock?

The financial health rating of INHIBRX BIOSCIENCES INC (INBX) is 4 / 10.